PharmedOut Fodder

Each month, the PharmedOut Newsletter covers a pressing issue on industry's influence on the medical world. You can read all of the Fodders on this page.

2024

March 2024: Proposed bill on off-label promotion gets pulled

February 2024: Painful Presentation: KOL gives problematic lecture on opioids

2023

December 2023: Rexulti ads: both depressing and agitating

October 2023: Pharma-funded groups pressure Medicare to cover obesity drugs 

September 2023: Is the Alzheimer's Association guiding patients to an early grave?

August 2023: Who's really behind the weight loss drug hype?

June & July 2023: Why we're salty with Jazz Pharmaceuticals and the AHA

May 2023: Why are opioids approved for chronic pain when they don’t work?

April 2023: Breathtaking Unbranded Marketing from Amgen

March 2023: Novo Nordisk outed for veiled marketing through third parties

February 2023: Bite-sized sponsored education is still advertising

January 2023: Overweight and Over Wegovy

2022

December 2022: Pharma's Payout to Nurse Practitioners and Physician Assistants

November 2022: Selling drugs and patients' bodies

October 2022: Health Union? More like, Stealth Union

September 2022: Does $500,000 a year for a drug make your eyes bulge? We have a drug for that...  

August 2022: Will California's opioid guidelines cave to industry pressure?  

July 2022: "Have your cake and eat it too": wood pulp for weight loss 

June 2022: Quivering with Quviviq: New sleep drug uses the same old marketing playbook 

May 2022: McKinsey & Company: Double Agent for Purdue and FDA 

March 2022: Let's lose the term "legitimate pain patient"

February 2022: "It's a trap!" A doctor and a patient duped by Pharma speak out 

2021

November 2021: Sales of Some Opioids Lift Sales of All Opioids

October 2021: The FDA Should Mandate Industry-free CME

September 2021: Manufacturing Doubt and Evading Responsibility

July 2021: What Does a "Human Rights" Frame for Pain Advocacy Look Like?

May/June 2021: Another Key Player in Purdue's Opioid Marketing Strategy

April 2021: New and Convenient Does Not Equal Better and Safe

March 2021: Opioid Marketing Tactics: The Old and the New

February 2021: Why is the AMA Promoting Opioid Use? 

January 2021: The House and the Senate Take on Opioid Marketing  

2020

December 2020: McKinsey Proposed What to Purdue? 

November 2020: Purdue's Most Successful Strategy No One Is Talking About

October 2020: Industry's Influence on Pain Patients' Advocacy

September 2020: The UK's Take on the Treatment of Chronic Primary Pain

August 2020: Yet Another Industry-Friendly Platform for Opioid Promotion

July 2020: Will the CDC Opioid Guideline Update be Informed by Scientific Evidence or Narrative?

June 2020: Asking About Pain Tolerance Could Lead to Fewer Opioid Prescriptions 

May 2020: Triplicate States and Opioid Prescribing

April 2020: Fact or Fiction? How Opioid Misinformation Continues Online

March 2020: We Know About Opioids, but Where Else Are Pharma Payments Going? 

February 2020: The Trouble with Tramadol

January 2020: Story vs. Anti-Story in Opioid Marketing

2019

December 2019: In Opioid Cases, Look to Tobacco Litigation for Guidance 

November 2019: When Sunshine Doesn't Cast Enough Light 

October 2019: Disinfecting Pharma with Sunshine: The Case for Bringing Documents to Light 

September/August 2019: Highlights from the Johnson & Johnson Opioids Verdict 

May 2019: Preventing a new generation of opioid “legacy patients”

April 2019: Who's Really Advocating for Pain Patients?

March 2019: Industry's Voice, Pain Patient's Face

February 2019: What Really Helps Chronic Pain Patients?

2018

December 2018:  An opioid treatment for depression nixed by FDA advisory committee

November 2018: Make Punishment Personal

October 2018: Greater Decline in Opioid Prescribing After CDC Guidelines Released

August 2018: A Million Ways to Market a Pill

July 2018: Subsys Sales, from Salacious to Scammy

May 2018: Pharma and the NIH: Innocence by Association?

April 2018: Purdue's Latest PR Move

March 2018: Rx Files: No Medication is Benign, Part 2

February 2018: Rx Files

January 2018: PharmedOut Review in Photos

2017 

December 2017: Final Nail in the Addyi Coffin?

November 2017: Joy's Favorite Article of the Month

October 2017: Live from capitol hill: McCaskill investigates Insys marketing practices

September 2017: Rx Files

August 2017: Rx Files

June 2017: When it comes to drug allergies: Time is money

April 2017: Orphan Drugs: Pharma's New Favorite Child

March 2017: Does Industry Influence Medical Discourse?

February 2017: Rx Files

January 2017: Live at the FDA

2016

December 2016: Rx Files

November 2016: Rx Files

October 2016: FDA Caves to Patient Pressure

September 2016: Rx Files

August 2016: Salespeople in the Surgical Suite

July 2016: Blood Money: Pharma Targets People with Hemophilia

June 2016: Pharma Backed Co-Pay Charities

May 2016: Pharma Should Invest in Take-Back Programs

April 2016: ProPublica Proves Why Lunch, and Other Gifts, Matter

March 2016: Problems With Clinical Trials

February 2016: Pharma's Role in the Opioid Crisis

January 2016: Unethical Trials on Unethically Long Shifts

2015

December 2015: Doctors Speak Out on DTC Advertising

November 2015: Pharma University

October 2015: Making an Example of Martin Shkreli

September 2015: Opioids for Kids

August 2015: Let's Keep Transparency in CME

July 2015: More on the Flibanserin Fight

June 2015: Psychiatry Under the Influence

May 2015: Burning Questions to be Answered at PharmedOut Conference

April 2015: 21st Century Pandering

March 2015: The Real Risks of Rx Drugs

February 2015: Demanding Results of Clinical Trials

January 2015: The Rising Costs of Prescription Drugs

2014

December 2014: There's a (Pharma) App for That

November 2014: Standards for FDA Drug Approval

October 2014: "Where's the Female Viagra?"

September 2014: When Pharma Meets Medical Journals

August 2014: Sunshine Still Misses CME

July 2014: What's in a Word?

June 2014: The Bullying of Journal Editors

May 2014: Transparency

April 2014: Attention Deficit Disorder/ Attention Deficit Hyperactivity Disorder

March 2014: Testosterone and Opioids (A Tie)